{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_000345.4:c.158A>T",
          "cDNA Change": {
            "transcript": "NM_000345.4",
            "ref": "A",
            "alt": "T",
            "position": "158"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "V",
            "position": "53"
          },
          "Description in input context": "c.158A>T (p.A53V)"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0005071"
  },
  "Experiment Method": [
    {
      "Assay Method": "Immunohistochemistry",
      "Material used": {
        "Material Source": "Postmortem brain tissue",
        "Material Name": "Brain regions including substantia nigra, putamen, locus coeruleus, olfactory tract, cingulate cortex, entorhinal cortex, hypothalamus, dorsal raphe nucleus, and hippocampus",
        "Description": "Paraffin-embedded sections of different brain regions were sectioned and immunostained with anti-a-syn mAbs LB509 and Syn303."
      },
      "Readout type": "Qualitative",
      "Readout description": [
        {
          "Variant": "NM_000345.4:c.158A>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Intermediate effect",
          "Result Description": "Large spheroids were particularly notable in the substantia nigra pars compacta, locus coeruleus, nucleus basalis of Meynert, hypothalamus, and CA2 of hippocampus. Smaller neuritic pathology was observed in cortical areas and the amygdala."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Sections from multiple brain regions of the same patient were analyzed."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Sections from a pathologically normal brain were used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Sections from a sporadic PD case without clinical dementia were used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "N.D.",
        "Source": "N.D."
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "N.D.",
        "Source": "N.D."
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Western Blotting",
      "Material used": {
        "Material Source": "Frozen brain tissue",
        "Material Name": "Cingulate cortex, midfrontal cortex, cerebellum, hippocampus, and subcortical areas",
        "Description": "Small samples of multiple brain regions were fractionated using buffers of increasing solubilization strengths."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000345.4:c.158A>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Intermediate effect",
          "Result Description": "A significant portion of a-syn in cingulate cortex from case IX-51 is extractable only with SDS, and a larger pool is solubilized only with FA."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Samples from multiple brain regions of the same patient were analyzed."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Sections from a pathologically normal brain were used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Sections from a sporadic PD case without clinical dementia were used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "N.D.",
        "Source": "N.D."
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "N.D.",
        "Source": "N.D."
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "In vitro fibril formation assays",
      "Material used": {
        "Material Source": "Recombinant proteins",
        "Material Name": "Recombinant WT and A53T mutant a-synuclein",
        "Description": "Purified recombinant proteins were incubated at 37°C with shaking, and fibril formation was detected by measuring K114 fluorescence as well as by sedimentation analyses."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000345.4:c.158A>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Gain-of-function",
          "Result Description": "Fibril assembly was much faster for A53T compared to WT a-syn, and coassembly experiments showed that the rates of assembly of a-syn and tau were accelerated when A53T instead of WT a-syn was used."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "N.D."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Four samples were used for each condition."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "WT a-syn was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Nonfibrillogenic D71–82 mutant a-syn and fibrillogenic amyloid Aβ(1–40) peptide were used as negative controls."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "Yes",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "No",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "N.D.",
        "Source": "N.D."
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "N.D.",
        "Source": "N.D."
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}